NEWS
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
Kronos Bio (NASDAQ: KRON) presented new preclinical data on istisociclib (KB-0742), a CDK9 inhibitor, at the AACR Ovarian Cancer Research Symposium. The data supports the clinical evaluation of istisociclib in advanced ovarian cancer, particularly in platinum and PARP-inhibitor resistant cases.
Key findings include:
Istisociclib triggered cell death in preclinical ovarian cancer models resistant to platinum and PARP inhibitors
New PK/PD results show sustained downregulation of CDK9-dependent genes in PBMCs with an 80mg dose on a 4 days on/3 days off schedule
Preclinical evidence suggests istisociclib induces DNA damage and subsequent cell death
Istisociclib disrupted homologous recombination DNA damage repair, creating a "BRCAness" phenotype in resistant cells
Kronos Bio is currently evaluating istisociclib in a Phase 1/2 clinical trial expansion cohort for platinum-resistant high-grade serous ovarian cancer (HGSOC).
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2314Followers
106Following
24KVisitors
Follow